Teva Pharmaceutical Industries Ltd (TEVA)

17.50
0.30 1.80
NYSE : Health Care
Prev Close 17.19
Open 17.25
Day Low/High 16.96 / 17.30
52 Wk Low/High 15.22 / 51.51
Volume 2.40M
Avg Volume 20.36M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 17.26B
EPS 0.10
P/E Ratio 3.31
Div & Yield 0.34 (2.00%)

Latest News

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Teva Pharmaceutical Industries Ltd. Investors (TEVA)

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Teva Pharmaceutical Industries Ltd. Investors (TEVA)

Law Offices of Howard G. Smith continues its investigation on behalf of Teva Pharmaceutical Industries Ltd.

Teva And Nuvelution Pharma Partner To Accelerate Development Of AUSTEDO® (deutetrabenazine) Tablets For Use In Tourette Syndrome In The United States

Teva And Nuvelution Pharma Partner To Accelerate Development Of AUSTEDO® (deutetrabenazine) Tablets For Use In Tourette Syndrome In The United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc.

Teva Completes Amendment To Credit Facilities

Teva Completes Amendment To Credit Facilities

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing Teva greater flexibility in its financial leverage ratio...

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

The S&P 500 and Dow score new records. Here's where stocks settled on Monday.

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

Stocks aim for new records. Here's where stocks are trading at the session midway mark on Monday.

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Stocks aim for new records with markets in a generally upbeat mood ahead of a decision on interest rates from the Federal Reserve this week.

New Initiative Creates Scalable Solutions To Improve Care Of Patients With Multiple Chronic Conditions

New Initiative Creates Scalable Solutions To Improve Care Of Patients With Multiple Chronic Conditions

Today, two leading private sector groups announced a partnership to create scalable solutions to improve patient and health system care for Multiple Chronic Conditions.

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Stocks aim for new records. Here's where stocks are trading at the market open on Monday.

Teva Announces Sale Of Remaining Assets In Specialty Global Women's Health Portfolio For $1.38 Billion

Teva Announces Sale Of Remaining Assets In Specialty Global Women's Health Portfolio For $1.38 Billion

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into two agreements to sell the remaining assets of its specialty global women's health business for $1.

Sentiment Makes a Dramatic Move

There are two distinct issues in the market right now.

Teva's New CEO Brings This Secret Weapon

Teva's New CEO Brings This Secret Weapon

The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Teva Pharmaceutical Industries Ltd. Shareholders And A Lead Plaintiff Deadline Of October 23, 2017

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Teva Pharmaceutical Industries Ltd. Shareholders And A Lead Plaintiff Deadline Of October 23, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd.

Teva To Present Data For AUSTEDO® (deutetrabenazine) Tablets And Other Research At The 2017 Psych Congress

Teva To Present Data For AUSTEDO® (deutetrabenazine) Tablets And Other Research At The 2017 Psych Congress

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the presentation of 12 posters at the upcoming 2017 Psych Congress, September 16-19 in New Orleans, Louisiana.

TEVA INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Teva Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of October 23, 2017

TEVA INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Teva Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of October 23, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Teva Pharmaceutical...

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Teva Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 23, 2017

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Teva Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 23, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired American Depositary Shares of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Has a Long Road Back

Teva Pharmaceutical Has a Long Road Back

Damage on TEVA's charts is significant.

How Did Teva Become a Pharmaceutical Giant?

How Did Teva Become a Pharmaceutical Giant?

In August 2016, Teva completed its purchase of Allergan's generic drug business for $33.4 billion in cash and $5.4 billion in stock

Teva Surges Once Again on $1.1 Billion Sale and New CEO

Teva Surges Once Again on $1.1 Billion Sale and New CEO

Teva's New York-listed shares were up 7.63% in premarket trading, indicated to open at $19.90

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Here's what you need to know now for Monday, September 11.

Teva Announces Sale Of PARAGARD® (intrauterine Copper Contraceptive) To CooperSurgical

Teva Announces Sale Of PARAGARD® (intrauterine Copper Contraceptive) To CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD ® (intrauterine copper contraceptive), a product...

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

Wall Street starts the week with a rally.

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

The Dow is up more than 250 points.

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

The world's biggest generic drug maker Monday named Kare Schultz as president and CEO, ending months of speculation about who would replace former head Erez Vigodman, who left the company in February for undisclosed reasons.

Midday Report: Stocks Moving Higher as Weaker Irma Shores Up Optimism

Midday Report: Stocks Moving Higher as Weaker Irma Shores Up Optimism

Stocks rose at midday Monday.

TheStreet Quant Rating: D+ (Sell)